IM Cannabis Corp. IMCC
Medicinal Chemicals and Botanical Products · data as of November 13, 2026
IM Cannabis Corp. (IMCC) is a healthcare company listed in the US with a market value of about $1M. In the twelve months to March 31, 2026 it had revenue of $36M and net income of -$10M, a net margin of -27.2%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is track record (2/5); the weakest is future growth (0/5).
Key numbers: a price to free cash flow of 30.5, 5-year revenue growth of 26% a year, a 5-year average ROIC of -52%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 1760% above the current price.
About IM Cannabis
IM Cannabis is listed in the US and classified in medicinal chemicals and botanical products. Revenue went from $7M in 2019 to $40M in 2025, growth of about 33.7% a year. It was profitable in 0 of the last 7 years in our data.
Score: 1.0 / 5
Checks passed
- Price below intrinsic value (DCF, moderate assumptions)
- 5-year revenue growth above 8% a year
- ROE above 15%
- Positive free cash flow
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $36M | $40M | $38M | $37M | $40M | $27M | $12M | $7M |
| Net income | -$10M | -$8M | -$7M | -$7M | -$140M | -$14M | -$23M | -$6M |
| Free cash flow | $34328 | $3M | -$856964 | -$7M | -$10M | -$31M | -$8M | -$6M |
| EPS (diluted) | $-5.27 | $-4.48 | $-3.99 | $-3.89 | $-75.66 | $-7.58 | $-12.21 | $-3.04 |
| Net margin | -27.2% | -20.7% | -19.6% | -19.5% | -347.6% | -52.2% | -180.6% | -80.4% |
| ROIC | — | -79.3% | -45.1% | -37.5% | -91.2% | -8.6% | -58.7% | -32.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is IM Cannabis stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 1760% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does IM Cannabis pay a dividend?
Not currently.
Is IM Cannabis a good stock to buy?
We do not give buy or sell advice. IM Cannabis scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.